Genomic Solution for Pet Antibody Target Discovery

Monoclonal antibodies (mAbs) have revolutionized human medicine, and this success is now being extended to companion animals, offering targeted therapies for a range of conditions, from cancer to chronic inflammatory diseases. The critical first step in developing these powerful biologics is the accurate identification and validation of a therapeutic target. Creative Biolabs specializes in pioneering genomic strategies to uncover novel antibody targets specifically for pet species, paving the way for the next generation of veterinary care.

Introduction to Genomic Target Discovery

Target discovery is the foundational process of identifying molecules, typically proteins or genes, that play a pivotal role in a disease. A successful therapeutic antibody must engage a target that is not only central to the disease's progression but also "druggable," meaning it is accessible and can be modulated by an antibody to achieve a therapeutic effect. Traditional target discovery methods have often relied on approaches that were not tailored to the unique genetic makeup of companion animals. Our genomic solution for pet antibody target discovery bypasses these limitations by going directly to the source: the genetic blueprint of the disease in the target species. By leveraging advanced genomic and bioinformatic technologies, we compare the genetic landscapes of healthy and diseased pet populations to pinpoint the specific genetic variations, mutations, or expression patterns that drive the pathology. This approach provides a robust, evidence-based foundation for your therapeutic antibody program, significantly increasing the probability of downstream success.

Curious about how a genomic approach can de-risk your veterinary drug discovery pipeline?

Request a Consultation

Workflow of Genomics based Antibody Target Discovery

At Creative Biolabs, we have engineered a systematic and efficient workflow to translate complex genomic data into a shortlist of high-value, validated targets for your pet therapeutic antibody projects.

Pet Antibody Target Genomics Discovery Workflow. (Creative Biolabs Original) Fig. 1 Genomics Pet Antibody Target Discovery Workflow. (Creative Biolabs Original)

1. Strategic Project Design & Cohort Selection	We begin with a deep dive into the specific disease indication. Our specialists collaborate with your team to define project goals and establish criteria for sourcing biological samples from relevant pet populations, ensuring a statistically powerful study design.
2. Next-Generation Sequencing (NGS)	Utilizing state-of-the-art sequencing platforms, we perform comprehensive genomic analyses, such as whole-genome sequencing (WGS) or whole-exome sequencing (WES), on samples from both diseased and healthy animal cohorts. This generates a massive dataset detailing the genetic variations across the populations.
3. Advanced Bioinformatic Analysis	Our proprietary bioinformatic pipelines process and analyze the raw sequencing data. We perform comparative genomics to identify disease-associated genetic markers, single nucleotide polymorphisms (SNPs), and gene copy number variations that are statistically significant in the affected animals.
4. Candidate Target Prioritization	The identified genetic markers are filtered through a multi-parameter assessment. We evaluate the "druggability" of the potential targets, their biological function, expression patterns, and any known association with similar pathways in other species to create a prioritized list of the most promising candidates.
5. Initial Target Validation	We confirm the link between the prioritized genes and the disease through a series of initial validation assays. This critical step provides the essential evidence needed to confidently move a target into the next phase of antibody discovery and development.

Why Choose Us?

(Creative Biolabs Authorized)

Unparalleled Focus on Companion Animal Genomics
Our expertise is deeply rooted in the unique genetics of companion animals. We understand the complexities and variations within and between breeds of dogs and cats, allowing us to design more accurate studies and interpret data with a level of nuance that is essential for success in veterinary medicine.
Cutting-Edge Technology Platforms
Our advanced NGS technologies and proprietary analytical tools enable us to detect even subtle genetic signals that are often missed by standard analysis methods, providing you with a distinct competitive advantage.
Seamless Integration with Downstream Antibody Development
Creative Biolabs offers a comprehensive suite of services for the entire antibody discovery pipeline. Our genomic discovery service integrates seamlessly with our other capabilities, including our Transcriptomic and Proteomic solutions, creating a powerful multi-omics approach for a holistic understanding of the target and its biological context.

FAQs

1. What types of pet diseases are most suitable for a genomic target discovery approach?

Genomic approach is highly effective for a wide range of diseases, particularly complex genetic disorders, cancers, and immunological conditions where genetic predispositions play a significant role. It is especially powerful for identifying novel targets in diseases with previously unknown or poorly understood mechanisms.

2. How does this genomic service differ from more traditional target discovery methods?

Traditional methods often rely on candidate approaches (studying genes already suspected to be involved in a disease) or using data from other species, which may not translate effectively to pets. Our genomic solution is an unbiased, "discovery" approach that surveys the entire genome to identify novel, species-specific targets that would likely be overlooked by older methods, opening up new therapeutic possibilities.

Related Services

Expand your discovery capabilities by integrating our genomic solution with other powerful platforms:

Transcriptomic Solution

Understand how gene expression is altered by disease to add another layer of evidence to your target validation.

Proteomic Solution

Directly identify and quantify disease-specific proteins in tissue and biofluids to confirm your target is expressed and accessible.

In Silico Target Screening

Utilize computational tools to predict the druggability and potential off-target effects of your prioritized candidates.

High-Throughput Target Screening

Functionally screen hundreds of potential targets in parallel to rapidly identify those that modify disease phenotype in cellular models.

Partner with Creative Biolabs

By harnessing the power of the genome, Creative Biolabs provides the most advanced and reliable path to discovering and validating the next wave of antibody targets for companion animals. Our dedicated focus, technological superiority, and integrated approach reduce risk and accelerate your timeline, moving you closer to delivering life-changing therapies to the pets who need them most.

Contact us today to discuss your project with a Creative Biolabs scientific liaison and discover how our genomic solution can empower your veterinary antibody discovery program.

Contact Our Team

Services